(VIANEWS) – Shares of Novavax (NASDAQ: NVAX) dropped by a staggering 15.86% in 5 sessions from $9.52 at -15.86, to $8.01 at 12:09 EST on Tuesday, after four sequential sessions in a row of losses. NASDAQ is rising 0.17% to $12,386.53, following the last session’s upward trend.
Novavax’s last close was $8.11, 89.44% under its 52-week high of $76.77.
About Novavax
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Earnings Per Share
As for profitability, Novavax has a trailing twelve months EPS of $-8.
Sales Growth
Novavax’s sales growth is 19.8% for the ongoing quarter and negative 57.7% for the next.
Moving Average
Novavax’s value is above its 50-day moving average of $7.48 and way below its 200-day moving average of $17.98.
More news about Novavax (NVAX).
